- Home
- PCH vs DYN Comparison
PCH vs DYN Comparison
Compare PCH & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCH
- DYN
- Stock Information
- Founded
- PCH 1903
- DYN 1984
- Country
- PCH United States
- DYN United States
- Employees
- PCH N/A
- DYN N/A
- Industry
- PCH Real Estate Investment Trusts
- DYN Medicinal Chemicals and Botanical Products
- Sector
- PCH Real Estate
- DYN Health Care
- Exchange
- PCH Nasdaq
- DYN Nasdaq
- Market Cap
- PCH 3.3B
- DYN 3.4B
- IPO Year
- PCH N/A
- DYN 2020
- Fundamental
- Price
- PCH $41.77
- DYN $28.39
- Analyst Decision
- PCH Buy
- DYN Strong Buy
- Analyst Count
- PCH 5
- DYN 9
- Target Price
- PCH $48.50
- DYN $52.44
- AVG Volume (30 Days)
- PCH 420.1K
- DYN 1.0M
- Earning Date
- PCH 10-28-2024
- DYN 11-12-2024
- Dividend Yield
- PCH 4.31%
- DYN N/A
- EPS Growth
- PCH N/A
- DYN N/A
- EPS
- PCH 0.20
- DYN N/A
- Revenue
- PCH $1,058,432,000.00
- DYN N/A
- Revenue This Year
- PCH N/A
- DYN N/A
- Revenue Next Year
- PCH $1.14
- DYN N/A
- P/E Ratio
- PCH $210.26
- DYN N/A
- Revenue Growth
- PCH 3.49
- DYN N/A
- 52 Week Low
- PCH $37.06
- DYN $9.82
- 52 Week High
- PCH $50.04
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- PCH 44.65
- DYN 42.04
- Support Level
- PCH $41.00
- DYN $27.99
- Resistance Level
- PCH $42.78
- DYN $35.68
- Average True Range (ATR)
- PCH 1.12
- DYN 2.09
- MACD
- PCH 0.02
- DYN 0.23
- Stochastic Oscillator
- PCH 52.84
- DYN 9.12
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.